Press "Enter" to skip to content

AstraZeneca sells infant drug rights to Sobi for $1.5 bln upfront

Around 130 AstraZeneca staff will transfer to Sobi as the Swedish company, widely known as Sobi, takes over marketing of the drug Synagis in the United States.

Original source:

Also Read:   RDIF submits application to WHO for prequalification of Sputnik V vaccine